The FDA announced AvKARE issued a voluntary recall of the depression drug trazodone (100 mg tablets) and the erectile dysfunction drug sildenafil (100 mg tablets) due to a possible mix-up.
Novo Nordisk initiated a phase IIIa trial to assess the GLP-1 receptor agonist semaglutide (Ozempic) as a possible early Alzheimer’s disease treatment. (Reuters)
Could a non-hallucinogenic version of ibogaine hold therapeutic potential for depression and addiction? (NPR)
Immediately prescribing metformin to kids with psychiatric conditions about to initiate an antipsychotic might help stave off the inevitable weight gain. (University of Houston)
New phase III data showed that the asenapine transdermal system (Secuado) — approved in October 2019 — significantly improved both positive and negative symptoms of schizophrenia over 6 weeks, Noven Pharmaceuticals announced. (Journal of Clinical Psychiatry)
According to 2014 CDC data, 19.2% of patients who visited the emergency department due to opioid use made two or more similar visits to the ED, with 1.2% dying within 30 days of discharge. (National Health Statistics Reports)
More and more college students may be at risk for developing depression as they are forced to isolate in their dorms. (Forbes)
Facebook may be able to pinpoint people suffering from mental illness, including schizophrenia, even a year before psychiatric hospitalization. (NPJ Schizophrenia)